Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Qilu Enters $300 Million Deal for Novel RNAi Hepatitis B Therapy

Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Arbutus Bio of Philadelphia . B-729, Arbutus’ lead candidate, is currently in multiple Phase IIa proof-of-concept clinical trials in combination with other approved or investigational agents. Qilu will pay $40 million upfront and make a $15 million investment in Arbutus. It will also be responsible for up to $245 million in milestone payments plus double digit royalties. More details.... Stock Symbol: (NSDQ: ABUS) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.